新诺威：控股子公司度普利尤单抗注射液获药物临床试验批准通知书

Core Viewpoint - The announcement indicates that the subsidiary of the company, Shiyao Group Jushi Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of Dupilumab injection, a biosimilar to Dupixent, aimed at treating moderate to severe atopic dermatitis in adults [1] Group 1 - The clinical trial approval for Dupilumab injection is a significant step for the company in the biopharmaceutical sector [1] - Dupilumab injection is a fully human monoclonal antibody targeting IL-4Rα, which positions it as a competitive product in the treatment of atopic dermatitis [1] - The drug is intended to serve as a biosimilar to Dupixent, which is already established in the market [1]